Call Options

15 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$191.51 - $216.16 $4.63 Million - $5.23 Million
24,200 Added 30.79%
102,800 $21.8 Million
Q2 2023

Aug 14, 2023

BUY
$187.64 - $206.25 $4.02 Million - $4.41 Million
21,400 Added 37.41%
78,600 $15.1 Million
Q1 2023

May 15, 2023

BUY
$127.59 - $203.08 $5.31 Million - $8.45 Million
41,600 Added 266.67%
57,200 $11.6 Million
Q4 2022

Feb 14, 2023

BUY
$117.37 - $139.17 $58,685 - $69,585
500 Added 3.31%
15,600 $2 Million
Q3 2022

Nov 14, 2022

BUY
$135.27 - $180.11 $2.04 Million - $2.72 Million
15,100 New
15,100 $2.07 Million
Q2 2022

Aug 15, 2022

SELL
$108.81 - $179.33 $533,169 - $878,717
-4,900 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$119.61 - $157.85 $586,089 - $773,465
4,900 New
4,900 $706,000
Q4 2021

Feb 14, 2022

BUY
$142.57 - $190.86 $99,799 - $133,602
700 Added 116.67%
1,300 $200,000
Q4 2021

Feb 14, 2022

SELL
$142.57 - $190.86 $185,341 - $248,118
-1,300 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$142.45 - $169.82 $85,470 - $101,892
600 New
600 $102,000
Q3 2021

Nov 15, 2021

SELL
$142.45 - $169.82 $2.14 Million - $2.55 Million
-15,000 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$135.08 - $161.1 $2.03 Million - $2.42 Million
15,000 New
15,000 $2.37 Million
Q1 2021

May 14, 2021

SELL
$137.51 - $190.8 $550,040 - $763,200
-4,000 Closed
0 $0
Q1 2021

May 14, 2021

SELL
$137.51 - $190.8 $1.98 Million - $2.75 Million
-14,400 Reduced 78.26%
4,000 $556,000
Q4 2020

Feb 16, 2021

BUY
$164.63 - $211.93 $3.03 Million - $3.9 Million
18,400 New
18,400 $3.23 Million

Others Institutions Holding SGEN

About Seagen Inc.


  • Ticker SGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,664,992
  • Description
  • Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...
More about SGEN
Track This Portfolio

Track Parallax Volatility Advisers, L.P. Portfolio

Follow Parallax Volatility Advisers, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.